Steven D. Gore MD

Director of Hematologic Malignancies

Clinical Interests

Leukemia, myelodysplastic syndrome


Board Certifications

1987
Internal Medicine, Board Certified
1989
Medical Oncology, Board Certified

Patient Care Locations

steven_gorefaculty-clinicsfalsetruetrue6truefalsefalse

Clinical Trials

ConditionsStudy Title
Myeloid and Monocytic LeukemiaE2905: Randomized Phase III Trial Comparing the Frequency of Major Erythroid Response (MER) to Treatment with Lenalidomide (Revlimid) Alone and in Combination with Epoetin Alfa (Procrit) in Subjects with Low- or Intermediate-1 Risk MDS and Symptomatic Anemia
Leukemia, not otherwise specified and Myeloid and Monocytic LeukemiaAn Open Label, Phase I/IIa, Dose Escalation Trial to Investigate the Maximum Tolerated Dose, Safety, Pharmacokinetics, and Efficacy of Intravenous Volasertib (BI 6727) in Combination with Decitabine in Patients with Acute Myeloid Leukemia
Leukemia, other(E1910) A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-negative B lineage Acute Lymphoblastic Leukemia in Adults
Leukemia, otherPhase III, Multicenter, Randomized, Trial of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection versus Cytarabine and Daunorubicin in Patients 60-75 Years of Age with Untreated High Risk (Secondary) AML
Leukemia, otherA Randomized Phase III Study of Bendamustine Plus Rituximab Versus Ibrutinib Plus Rituximab Versus Ibrutinib Alone in Untreated Older Patients (=65 Years of Age) with Chronic Lymphocytic Leukemia (CLL)

More Clinical Trials...

Edit Profile